Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 24, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 775,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,162.0 pence per share; lowest price paid was 1,150.0 pence per share.
- Treasury Shares Held: 493,224,284 shares (8.70% of total issued share capital; 9.53% of total voting rights).
- Shares in Issue: 5,174,541,085 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the purchase and subsequent cancellation of 775,000 shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share repurchase.
Investor Verification Checklist
- Verify the total number of shares in issue (5,174,541,085) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the impact of the 775,000 share cancellation on the total issued share capital.
- Note that the Treasury share holding represents 9.53% of total voting rights.
- Recognize that this document does not contain financial performance data; refer to Form 20-F for full financial results.